第二个协调球调节纳米酶抑制,以协助早期药物发现
Yu Wu1, Jian Li1, Wenxuan Jiang1
1State Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensing Technology and Health, College of Chemistry, Central China Normal University, Wuhan, PR China.
Nature communications
|April 1, 2025
概括
研究人员开发了一种新型纳米酶 (CuNC-OH),可以模仿酶活性位点,用于药物发现. 这种纳米酶通过分析抑制特征,使抗甲状腺药物的成本有效选成为可能,从而加速早期药物开发.
科学领域:
- 生物化学 生化学
- 材料科学 材料科学 材料科学
- 药物发现 药物发现 药物发现
背景情况:
- 模仿酶的纳米酶对于早期药物发现至关重要,但往往缺乏自然酶的精确活性部位配置.
- 纳米酶的第二协调球的合理设计对于增强类似酶的活性至关重要,但仍然是一个重大挑战.
研究的目的:
- 设计和描述一种具有原子分散 Cu-N4 位点和近接基组 (CuNC-OH) 的新型纳米酶,该纳米酶有效模仿酶囊.
- 阐明设计的纳米酶的作用机制及其与吸附剂的相互作用.
- 建立一个纳米酶辅助的药物发现工具包,用于选抗甲状腺药物.
主要方法:
- 合成和表征CuNC-OH纳米酶与原子分散的Cu-N4位点和基团.
- 实验和理论研究以了解双位点相互作用机制 (Cu-N4位点和基组).
- 开发一种基于纳米酶的工具包,用于分析甲状腺过氧化酶抑制剂活性和查抗甲状腺药物.
主要成果:
- CuNC-OH纳米酶成功地模仿了酶口袋,Cu-N4位点作为辅因子,基组作为氨基酸.
- 双位点机制使得抗甲状腺药物能够对纳米酶进行特定的抑制,类似于甲状腺过氧化剂.
- 开发的纳米酶套件有效地分析抑制特征,并以降低成本选抗甲状腺药物.
结论:
- 具有双活性位点的纳米酶的理性设计为模仿药物发现中的酶功能提供了一个有希望的策略.
- NC-OH纳米酶为选甲状腺过氧化酶抑制剂和开发新型抗甲状腺药物提供了具有成本效益和高效的平台.
- 这种方法显著提升了基于纳米酶的药物发现工具的能力.
相关概念视频
01:30Enzyme Inhibition
77.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.5K
01:26Drug Discovery: Overview
7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
01:26Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
02:34Enzymes
80.2K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
80.2K
01:08Allosteric Regulation
57.2K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.2K
01:25Drug-Receptor Bonds
2.6K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.6K